PROVISION OF DRUGS FOR PATIENTS WITH BIPOLAR AFFECTIVE DISORDERS

Download full text PDF
DOI: https://doi.org/None
Issue: 
3
Year: 
2015

R.I. Yagudina, PhD; I.A. Komarov I.M. Sechenov First Moscow State Medical University; 8, Trubetskaya St., Build. 2, Moscow 119991

Bipolar affective disorders (BADs) manifest themselves in about 2 per 100 people in the population. These are chronic, deconditioning diseases characterized by maniac, depressive, and mixed episodes that are frequently accompanied by behavioral, cognitive, and perceptual impairments. Moreover, BADs belong to a group of diseases that have a significant impact on the patients’ quality of life, suggesting the need to provide effective drug care for this contingent of patients. Within the scope of this investigation, the authors made a multifaceted analysis of the volumes and trends of drug use to treat BADs, by thoroughly studying these indicators for a new group of atypical antipsychotics (AAs) having high efficacy. They explored a trend in drug consumption for the treatment of BADs in terms of money and quantities for the period 2009-2013; a trend in drug usage for the treatment of BADs by pharmaceutical market sectors in terms of money and quantities; the tops of international nonproprietary names and trade names of drugs for the treatment in terms of money and quantities in different sectors of the pharmaceutical market.
Keywords: 
drug provision
bipolar affective disorders
drug therapy
drug usage
psychiatry
References: 
  1. Üstün T.V., Sartorius N. Mental Illnessingeneral Healthcare, John Wiley&Sons, Inc., New York 199512.
  2. Alonso J., Angermeyer M.C., Bernert S. et al. Sampling and methods of the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica, 109 (suppl. 420), 8–20, 2004.
  3. Kessler R.C., Mc Gonagle K.A., Zhao S. et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 2005; 518–519.
  4. http://www.who.int/mental_health/mhgap/evidence/psychosis/en/
  5. Mosolov S.N. Klinika i terapiya maniakal`nyh i smeshannyh sostoyaniy v kn.: Bipolyarnoe affektivnoe rasstroystvo. M.: Medpress-inform, 2008; 62–127.
  6. Ekman M., Lindgren R., Miltenburger S. Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode. Pharmacoeconomics. 2012; 30 (6): 513–530.
  7. www.dsm.ru
  8. Yagudina R.I., Pravdyuk N.G. Ocenka tehnologiy zdravoohraneniya na urovne lechebno-profilakticheskogo uchrezhdeniya – aktual`nost` problemy. Sovremennaya organizaciya lekarstvennogo obespecheniya. 2013; 3: 5–10.
  9. Yagudina R.I., Litvinenko M.M., Zelenova E.G. Normativno-pravovoe regulirovanie obespecheniya kachestva i dostupnosti lekarstvennyh sredstv v Rossiyskoy Federacii. Sovremennaya organizaciya lekarstvennogo obespecheniya, 2013;1: 28–40.
  10. Rasporyazhenie Pravitel`stva RF № 2199-r ot 07.12.2011 «Ob utverzhdenii Perechnya zhiznenno neobhodimyh i vazhneyshih lekarstvennyh preparatov (ZhNVLP) na 2012 god».
  11. http://www.rosminzdrav.ru/
  12. Prikaz Ministerstva zdravoohraneniya i social`nogo razvitiya RF №665 ot 18.09.2006 «Ob utverzhdenii Perechnya lekarstvennyh sredstv, otpuskaemyh po receptam vracha (fel`dshera) pri okazanii dopolnitel`noy besplatnoy medicinskoy pomoshhi otdel`nym kategoriyam grazhdan, imeyushhim pravo na poluchenie gosudarstvennoy social`noy pomoshhi».
  13. Prikaz Ministerstva zdravoohraneniya RF №1419n ot 22.04.2013 g. «Ob utverzhdenii standarta skoroy medicinskoy pomoshhi pri rasstroystvah nastroeniya (affektivnyh rasstroystvah)».
  14. http://serbsky.ru/index.php?option=com_content&view=article&id=76&Itemid=68
  15. Prikaz Minzdrava Rossii № 1661n ot 29.12.2012 «Ob utverzhdenii standarta specializirovannoy medicinskoy pomoshhi pri depressii (recidiv) v stacionarnyh usloviyah».
  16. Prikaz Minzdrava Rossii № 1226n ot 20.12.2012 «Ob utverzhdenii standarta pervichnoy mediko-sanitarnoy pomoshhi pri depressiyah (remissii) v ambulatornyh usloviyah psihonevrologicheskogo dispansera (dispansernogo otdeleniya, kabineta)».
  17. Yagudina R.I., Yusupova S.D., Nazarenko P.V. Ispol`zovanie farmakoe`pidemiologicheskih metodov v sovremennoy farmacii. M.:MMA im. I.M. Sechenova, 2003; 64.
  18. http://grls.rosminzdrav.ru/
  19. Postanovlenie Pravitel`stva RF № 890 ot 30.07.1994 (red. ot 14.02.2002) «O gosudarstvennoy podderzhke razvitiya medicinskoy promyshlennosti i uluchshenii obespecheniya naseleniya i uchrezhdeniy zdravoohraneniya lekarstvennymi sredstvami i izdeliyami medicinskogo naznacheniya».